Clinical Trial Detail

NCT ID NCT03616470
Title Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlycoMimetics Incorporated
Indications

acute myeloid leukemia

Therapies

Cytarabine + Etoposide + Mitoxantrone + Uproleselan

Cytarabine + Fludarabine + Idarubicin + Uproleselan

Cytarabine + Etoposide + Mitoxantrone

Cytarabine + Fludarabine + Idarubicin

Age Groups: senior adult

No variant requirements are available.